107 related articles for article (PubMed ID: 15850464)
1. Mutations in the E2-PePHD region of hepatitis C virus type 1b in patients with hepatocellular carcinoma.
Bagaglio S; De Mitri MS; Lodrini S; Paties C; Cassini R; Bianchi G; Bernardi M; Lazzarin A; Morsica G
J Viral Hepat; 2005 May; 12(3):243-50. PubMed ID: 15850464
[TBL] [Abstract][Full Text] [Related]
2. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma.
Hiasa Y; Kamegaya Y; Nuriya H; Onji M; Kohara M; Schmidt EV; Chung RT
Am J Gastroenterol; 2003 Nov; 98(11):2528-34. PubMed ID: 14638359
[TBL] [Abstract][Full Text] [Related]
4. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
[TBL] [Abstract][Full Text] [Related]
5. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
De Mitri MS; Cassini R; Morsica G; Bagaglio S; Andreone P; Loggi E; Muratori P; Bernardi M
J Viral Hepat; 2006 Sep; 13(9):574-81. PubMed ID: 16907843
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma.
Zekri AR; Bahnassy AA; Hafez M; El-Shehaby AM; Sherif GM; Khaled HM; Zakhary N
J Gastroenterol Hepatol; 2005 Jan; 20(1):87-94. PubMed ID: 15610452
[TBL] [Abstract][Full Text] [Related]
7. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
Momosaki S; Nakashima Y; Kojiro M; Tabor E
J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
[TBL] [Abstract][Full Text] [Related]
8. CD81 nucleotide mutation in hepatocellular carcinoma and lack of CD81 polymorphism in patients at stages of hepatitis C virus infection.
Itakura J; Nagayama K; Enomoto N; Sakamoto N; Tazawa J; Izumi N; Marumo F; Sato C
J Med Virol; 2001 Jan; 63(1):22-8. PubMed ID: 11130883
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the inhibitory effect of antisense oligodeoxynucleotides on the growth of hepatitis C-associated hepatocellular carcinoma cells in vitro.
Amin MA; Awadein MR; Gabr H
Chin J Dig Dis; 2005; 6(3):142-8. PubMed ID: 16045605
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma.
Zhang KY; Imazeki F; Fukai K; Arai M; Kanda T; Mikata R; Yokosuka O
Cancer Sci; 2007 Dec; 98(12):1921-9. PubMed ID: 17888035
[TBL] [Abstract][Full Text] [Related]
11. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4.
Zekri AR; Bahnassy AA; Abdel-Wahab SA; Khafagy MM; Loutfy SA; Radwan H; Shaarawy SM
J Gastroenterol Hepatol; 2009 Mar; 24(3):416-28. PubMed ID: 19054267
[TBL] [Abstract][Full Text] [Related]
12. Variation of hepatitis C virus load, hypervariable region 1 quasispecies and CD81 hepatocyte expression in hepatocellular carcinoma and adjacent non-cancerous liver.
Young KC; Lin PW; Hsiao WC; Chang TT; Chang YC; Wu HL
J Med Virol; 2002 Oct; 68(2):188-96. PubMed ID: 12210407
[TBL] [Abstract][Full Text] [Related]
13. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma.
Hung CH; Chen CH; Lee CM; Wu CM; Hu TH; Wang JH; Yen YH; Lu SN
J Viral Hepat; 2008 Jan; 15(1):58-65. PubMed ID: 18088246
[TBL] [Abstract][Full Text] [Related]
14. Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b.
Nishise Y; Saito T; Sugahara K; Ito JI; Saito K; Togashi H; Nagano-Fujii M; Hotta H; Kawata S
J Infect Dis; 2007 Oct; 196(7):1006-9. PubMed ID: 17763321
[TBL] [Abstract][Full Text] [Related]
15. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma.
Hu Z; Muroyama R; Kowatari N; Chang J; Omata M; Kato N
Cancer Sci; 2009 Dec; 100(12):2465-8. PubMed ID: 20175782
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus genotypes and the development of hepatocellular carcinoma.
Stankovic-Djordjevic D; Djordjevic N; Tasic G; Dinic M; Karanikolic A; Pesic M
J Dig Dis; 2007 Feb; 8(1):42-7. PubMed ID: 17261134
[TBL] [Abstract][Full Text] [Related]
17. Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray.
Iizuka N; Oka M; Yamada-Okabe H; Hamada K; Nakayama H; Mori N; Tamesa T; Okada T; Takemoto N; Matoba K; Takashima M; Sakamoto K; Tangoku A; Miyamoto T; Uchimura S; Hamamoto Y
Int J Oncol; 2004 Mar; 24(3):565-74. PubMed ID: 14767541
[TBL] [Abstract][Full Text] [Related]
18. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
Polyak SJ; Nousbaum JB; Larson AM; Cotler S; Carithers RL; Gretch DR
J Infect Dis; 2000 Aug; 182(2):397-404. PubMed ID: 10915068
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma.
RĂ¼ster B; Zeuzem S; Roth WK
Biochem Biophys Res Commun; 1996 Feb; 219(3):911-5. PubMed ID: 8645278
[TBL] [Abstract][Full Text] [Related]
20. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
Ogura S; Akuta N; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Kobayashi M; Suzuki F; Suzuki Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2009; 52(4):179-88. PubMed ID: 19546575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]